🔍

IOLCP - IOL Chemicals

📊 NSE: IOLCP 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 8:25

📢 Recent Corporate Announcements

IOL Chemicals Reports 100% Compliance with SEBI Insider Trading Regulations for Q4 FY26

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 17 Apr 2026, 05:48 PM

IOL Chemicals and Pharmaceuticals Limited has filed its compliance certificate for the Structured Digital Database (SDD) for the quarter ended March 31, 2026. The company confirmed that it has maintained a non-tamperable internal database to track Unpublished Price Sensitive Information (UPSI) as per SEBI regulations. During the quarter, the company identified 1 UPSI event and successfully captured it within the system. No instances of non-compliance were reported, reflecting strong adherence to corporate governance and insider trading norms.

Successfully captured 1 out of 1 required UPSI events during the quarter ended March 31, 2026.
Maintained a non-tamperable Structured Digital Database (SDD) with an 8-year record retention capability.
Confirmed zero instances of non-compliance with SEBI (Prohibition of Insider Trading) Regulations.
Internal audit trails and access controls are in place to monitor UPSI dissemination.

💡 This is a routine regulatory filing that confirms the company's commitment to corporate governance. No immediate action is required as it does not impact the company's financial performance or business operations.

IOLCP Launches 100-Day 'Saksham Niveshak' Campaign for Unclaimed Dividends and KYC Updates

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Apr 2026, 03:02 PM

IOL Chemicals and Pharmaceuticals Limited has joined the Ministry of Corporate Affairs' 'Saksham Niveshak' campaign running from April 1 to July 9, 2026. The initiative focuses on assisting shareholders in claiming unpaid dividends for the period FY 2019-20 to FY 2025-26. It also mandates the update of KYC details like PAN and bank mandates to ensure electronic credit of future dividends. This move aims to prevent the transfer of unclaimed assets to the Investor Education and Protection Fund (IEPF).

100-day campaign 'Saksham Niveshak' active from April 1, 2026, to July 9, 2026
Targets unclaimed dividends for the 7-year period from FY 2019-20 to FY 2025-26
Mandatory KYC updates required for PAN, bank mandates, and nomination details
Unclaimed dividends and shares risk transfer to IEPF if not claimed within the stipulated period

💡 Shareholders should verify their status on the company's website and update KYC details by July 9, 2026, to avoid dividend withholding. This is a routine administrative update with no impact on the company's fundamental valuation.

IOLCP Announces Trading Window Closure from April 1, 2026 for Q4 and FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Mar 2026, 11:16 AM

IOL Chemicals and Pharmaceuticals Limited (IOLCP) has announced the closure of its trading window starting April 1, 2026, in compliance with SEBI Insider Trading Regulations. This closure is ahead of the declaration of the company's audited financial results for the quarter and full year ending March 31, 2026. The restriction applies to all designated persons and their immediate relatives. The trading window will remain closed until 48 hours after the financial results are officially announced to the exchanges.

Trading window closure effective from April 1, 2026.
Closure is for the purpose of finalizing audited financial results for Q4 and FY ended March 31, 2026.
Trading restriction ends 48 hours after the board meeting results are declared.
Compliance follows SEBI (Prohibition of Insider Trading) Regulations, 2015.

💡 This is a routine regulatory announcement with no impact on company fundamentals; investors should monitor for the upcoming board meeting date to review the Q4 and FY26 performance.

IOLCP Promoter Group Entity NCVI Enterprises Acquires 4.04 Lakh Shares for ₹3.01 Crore

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 20 Mar 2026, 01:03 PM

NCVI Enterprises Limited, a promoter group entity of IOL Chemicals and Pharmaceuticals Limited, has increased its stake in the company through an open market purchase. The entity acquired 4,04,305 equity shares on March 19, 2026, for a total consideration of approximately ₹3.01 crore. This transaction has resulted in the promoter group's holding rising from 16.44% to 16.58%. Such insider buying is generally perceived as a positive signal, indicating management's confidence in the company's intrinsic value and future growth.

Promoter group entity NCVI Enterprises Limited purchased 4,04,305 equity shares.
The acquisition was valued at approximately ₹3.01 crore via open market transactions.
The promoter group's stake increased from 16.44% to 16.58% following the purchase.
The transaction was executed on March 19, 2026, and officially disclosed on March 20, 2026.

💡 Investors should take note of this promoter buying as a sign of internal confidence in the company's prospects. It serves as a positive secondary indicator for long-term holders, though it should be weighed alongside broader fundamental performance.

Promoter Group Entity Buys 6.54 Lakh Shares of IOLCP for ₹4.47 Crore

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 18 Mar 2026, 03:15 PM

Mayadevi Polycot Limited, a promoter group entity of IOL Chemicals and Pharmaceuticals Limited, has acquired 6,54,123 equity shares through an open market transaction on March 17, 2026. The total acquisition cost was approximately ₹4.47 crore, increasing the entity's stake from 21.54% to 21.76%. This insider purchase is a positive signal, often indicating that the promoter group believes the company's shares are undervalued or has confidence in future growth.

Acquisition of 6,54,123 equity shares by promoter group entity Mayadevi Polycot Limited
Total transaction value of ₹4,47,17,289 executed via on-market purchase
Promoter entity's stake increased from 21.54% to 21.76% (a 0.22% increase)
Transaction occurred on March 17, 2026, and was disclosed to exchanges on March 18, 2026

💡 Investors should view this promoter buying as a sign of internal confidence in the company's prospects. It may serve as a support level for the stock price, though overall market conditions and sector performance should also be considered.

IOL Chemicals Promoter Group NCVI Enterprises Acquires 7 Lakh Shares via Open Market

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 18 Mar 2026, 03:01 PM

NCVI Enterprises Limited, a promoter group entity of IOL Chemicals and Pharmaceuticals Limited (IOLCP), has increased its stake in the company through an open market purchase. On March 16, 2026, the entity acquired 7,00,000 equity shares, representing approximately 0.24% of the company. This transaction raises the promoter group's holding from 15.96% to 16.20%. Such insider buying is generally interpreted as a positive signal of management's confidence in the company's long-term value.

Promoter group entity NCVI Enterprises Limited acquired 7,00,000 equity shares on March 16, 2026.
The acquisition was executed through an open market transaction.
The promoter group's total shareholding increased from 4,68,50,695 shares (15.96%) to 4,75,50,695 shares (16.20%).
The disclosure was filed under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations.

💡 Promoter buying at market prices often suggests that the leadership believes the stock is undervalued or has strong growth potential. Investors should maintain a positive outlook but continue to monitor the company's quarterly earnings performance.

IOLCP Clarifies Q3 FY26 Financial Results Format and Subsidiary Operations

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 17 Mar 2026, 12:22 PM

IOL Chemicals and Pharmaceuticals Limited (IOLCP) has responded to a clarification request from the National Stock Exchange regarding its Q3 FY2025-26 financial results. The company confirmed that its financial statements comply with Indian Accounting Standards (Ind AS) and Schedule III of the Companies Act, 2013. The similarity between standalone and consolidated figures is attributed to the fact that most subsidiaries have not yet commenced business operations. Only one subsidiary, incorporated under Section 8, is active, leading to minor differences in profit and depreciation figures.

Company confirms Q3 FY26 results follow Ind AS and Schedule III formats without deviation.
Standalone and Consolidated figures are nearly identical as most subsidiaries are non-operational.
Only one Section 8 subsidiary is active, resulting in minor differences in profit, depreciation, and expenses.
The clarification was issued in response to an NSE query dated March 11, 2026.

💡 This is a routine regulatory clarification and does not impact the company's fundamental performance. Investors should monitor the commencement of operations in subsidiaries for future consolidated growth.

IOLCP Receives EDQM CEP Certificate for Metformin Hydrochloride Process-II

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 06 Mar 2026, 03:52 PM

IOL Chemicals and Pharmaceuticals Limited (IOLCP) has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Health Care (EDQM) for its API product, Metformin Hydrochloride Process-II. This certification, granted on March 5, 2026, is an addition to the company's existing valid CEP for Metformin Hydrochloride. Metformin is a widely used antidiabetic drug for managing blood sugar levels. This regulatory milestone strengthens the company's ability to supply this critical API to the European market and other regions that recognize EDQM standards.

EDQM granted the CEP for Metformin Hydrochloride Process-II on March 5, 2026
The new certification is in addition to the existing valid CEP already held by the company
Metformin Hydrochloride is a key antidiabetic drug used globally for blood sugar management
The approval enhances IOLCP's regulatory compliance and market access in European territories

💡 Investors should view this as a positive development that reinforces IOLCP's position in the global API market. The additional certification may lead to improved operational flexibility and potential volume growth in the antidiabetic segment.

IOLCP Expands Ethyl Acetate and Acetic Anhydride Capacities via Rs 9.71 Cr Capex

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 02 Mar 2026, 06:56 PM

IOL Chemicals and Pharmaceuticals Limited has successfully completed the expansion of its manufacturing facilities for Ethyl Acetate and Acetic Anhydride as of March 2, 2026. The Ethyl Acetate capacity has been increased by 20,000 MTPA to reach 1,20,000 MTPA, while Acetic Anhydride capacity grew by 7,000 MTPA to 32,000 MTPA. The total project cost of Rs 9.71 crore was entirely funded through internal accruals, indicating a healthy balance sheet. This expansion is strategically timed as existing facilities were operating at 90-100% utilization.

Ethyl Acetate capacity increased from 1,00,000 MTPA to 1,20,000 MTPA (20% increase)
Acetic Anhydride capacity enhanced from 25,000 MTPA to 32,000 MTPA (28% increase)
Total capital expenditure of Rs 9.71 crore funded through internal accruals
Expansion completed on March 2, 2026, to address high utilization rates and market demand
Aims to improve margin realization through optimum operating leverage

💡 Investors should view this as a positive growth signal as the company is expanding capacity in segments where it already has high utilization. The use of internal accruals for capex further strengthens the investment case by avoiding additional debt.

IOLCP Q3 FY26 Revenue Up 11% to ₹580 Cr; EBITDA Grows 23% with 10.7% Margin

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 18 Feb 2026, 02:03 PM

IOL Chemicals and Pharmaceuticals reported a resilient Q3 FY26 with revenue growing 10.9% YoY to ₹580 crores and EBITDA rising 22.8% to ₹62.6 crores. The company's diversification strategy is yielding results, with non-ibuprofen APIs now contributing ₹128 crores to the pharmaceutical segment. Despite persistent high fuel costs in Punjab, management expects a 1-2% margin improvement in Q4 FY26. The board declared a 50% interim dividend, and the company maintains a positive growth guidance of 10-15% for FY27.

Revenue from operations increased 10.9% YoY to ₹580 crores, while EBITDA grew 22.8% to ₹62.6 crores.
Non-ibuprofen API portfolio contributed ₹128 crores, reflecting successful diversification away from core ibuprofen products.
Capacity utilization remains robust with Ibuprofen at 90-95% and the Chemicals division at nearly 100%.
Management guided for 10-15% top-line and 15-20% bottom-line growth in FY27, supported by ₹150-200 crore annual capex.
Reported a non-recurring exceptional item of ₹11.2 crores pertaining to new labor law provisions.

💡 Investors should focus on the improving product mix and the ramp-up in paracetamol capacity as key growth drivers. The stock remains a solid play on API diversification and backward integration efficiencies.

IOLCP Discloses Audio Recording Link for Q3 & M9 FY26 Earnings Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Feb 2026, 06:03 PM

IOL Chemicals and Pharmaceuticals Limited has released the audio recording of its investor call held on February 12, 2026. The call focused on the company's financial performance for the third quarter and nine months ended December 31, 2025 (FY26). This disclosure is a standard regulatory requirement under SEBI (LODR) Regulations, 2015, ensuring transparency for all shareholders. Investors can access the recording via the provided link to understand management's commentary on operational performance and future outlook.

Audio recording of the Q3 & M9 FY26 earnings call is now available for public access.
The call was conducted on February 12, 2026, following the release of quarterly financial results.
Compliance update submitted under Regulation 30 of SEBI (LODR) Regulations, 2015.
The recording provides management insights into the company's performance for the nine-month period ending FY26.

💡 Investors should listen to the recording to gain insights into the company's margin trends and management's guidance for the upcoming quarters. No immediate trading action is required based solely on this procedural filing.

IOLCP Declares Rs 1 Interim Dividend; Sets Feb 17 as Record Date for FY 2025-26

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 12 Feb 2026, 04:36 PM

IOL Chemicals and Pharmaceuticals Limited (IOLCP) has declared an interim dividend of Rs 1 per equity share, representing 50% of the face value of Rs 2, for the financial year 2025-26. The company has designated February 17, 2026, as the record date to identify eligible shareholders for this payout. Detailed guidelines for Tax Deduction at Source (TDS) have been issued, including a 20% deduction rate for accounts without a valid or linked PAN. Resident individual shareholders are exempt from TDS if their total dividend income from the company does not exceed Rs 10,000 during the fiscal year.

Interim dividend of Rs 1 per share (50% of face value) declared for FY 2025-26
Record date for dividend entitlement is fixed for February 17, 2026
TDS of 20% applicable for shareholders with invalid or non-Aadhaar linked PAN
Exemption from TDS for resident individuals if total dividend is below Rs 10,000
Deadline for submitting tax exemption forms (15G/15H) is February 17, 2026

💡 Investors should ensure their PAN is correctly linked and bank details are updated in their demat accounts before the record date. Eligible shareholders should submit Form 15G/15H through the Alankit Assignments portal by February 17 to avoid unnecessary tax deductions.

IOLCP Q3 FY26 Results: EBITDA Grows 22.8% YoY to ₹62.6 Cr; Revenue Up 10.9%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 12 Feb 2026, 12:49 PM

IOL Chemicals and Pharmaceuticals Limited (IOLCP) reported a steady Q3 FY26 performance with revenue growing 10.9% YoY to ₹580.4 Cr. EBITDA margins improved to 10.7% from 9.7% YoY, while PBT before exceptional items surged 39.3% to ₹38.8 Cr. The bottom line was slightly impacted by an exceptional charge of ₹11.2 Cr related to new labour code provisions. The company is successfully diversifying its portfolio, with the non-Ibuprofen segment now contributing significantly to growth.

Revenue from operations increased 10.9% YoY to ₹580.4 Cr in Q3 FY26.
EBITDA grew 22.8% YoY to ₹62.6 Cr with margins expanding by 100 bps to 10.7%.
PBT before exceptional items rose 39.3% YoY to ₹38.8 Cr.
Commenced New Unit 11 for Paracetamol with a significant installed capacity of 10,800 MTPA.
Maintains a very strong financial position with a Debt-to-Equity ratio of 0.07.

💡 Investors should focus on the company's successful transition from an Ibuprofen-heavy player to a diversified API manufacturer. The massive expansion in Paracetamol capacity and low leverage provide a strong foundation for long-term growth.

IOLCP Q3 FY26 Results: PBT Jumps 39.3% YoY to ₹38.8 Cr; Pharma Revenue Up 18%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 06:14 PM

IOL Chemicals and Pharmaceuticals (IOLCP) reported a robust Q3 FY26 performance with revenue growing 10.9% YoY to ₹580.4 crore. Profit Before Tax (before exceptional items) surged by 39.3% YoY to ₹38.8 crore, supported by a 102 bps expansion in EBITDA margins to 10.7%. The growth was largely driven by the Pharmaceuticals segment, which saw an 18% revenue increase and now accounts for 61% of the total revenue mix, up from 57% last year.

Revenue from operations increased 10.9% YoY to ₹580.4 Cr in Q3 FY26.
PBT (before exceptional items) grew 39.3% YoY to ₹38.8 Cr with a margin of 6.6%.
Pharmaceuticals segment EBIT rose 32% YoY to ₹34.5 Cr, driven by non-Ibuprofen APIs.
Chemicals segment EBIT grew 37% YoY to ₹6.5 Cr despite flat revenue growth.
9M FY26 EBITDA stands at ₹196.1 Cr, up 24.8% compared to the previous year.

💡 Investors should note the positive shift in product mix towards the higher-margin Pharmaceutical segment and the successful diversification into non-Ibuprofen APIs. The consistent margin expansion over the nine-month period suggests strong operational efficiency and resilience against global headwinds.

IOLCP Reports Q3 Revenue Growth of 11% YoY and Declares ₹1 Interim Dividend

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 02:51 PM

IOL Chemicals and Pharmaceuticals (IOLCP) reported a 10.9% YoY increase in Q3 FY26 revenue to ₹580.39 crore. The company declared an interim dividend of ₹1 per share (50% of face value) with a record date of February 17, 2026. Net profit for the quarter remained flat at ₹20.58 crore, primarily due to an exceptional item of ₹11.21 crore. However, the nine-month performance remains strong with PAT rising 21.8% to ₹84.54 crore compared to the previous year.

Declared an interim dividend of ₹1 per equity share (50% of FV ₹2) with Record Date as Feb 17, 2026.
Q3 Revenue from operations increased by 10.9% YoY to ₹580.39 crore from ₹523.30 crore.
Nine-month (9M FY26) Net Profit grew by 21.8% to ₹84.54 crore from ₹69.38 crore YoY.
Pharmaceutical segment revenue grew to ₹356.05 crore in Q3, up from ₹300.58 crore in the same quarter last year.
Reported an exceptional item of ₹11.21 crore during the quarter, which impacted the quarterly profit before tax.

💡 Investors should note the record date of February 17 for dividend eligibility. The steady revenue growth in the pharmaceutical segment is a positive indicator for long-term growth despite the quarterly impact of exceptional items.

View All IOLCP Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

In Q2 FY26, total revenue from operations reached INR 567.5 Cr, reflecting a 7.9% YoY growth. Historically, in FY24, the Pharma segment remained stable with a marginal 0.3% increase, while the Chemical segment saw a 9% decline due to pricing pressures. The company is currently targeting a 10-15% annual revenue growth across segments.

Geographic Revenue Split

The company is strategically shifting from domestic to regulated markets (Europe and US) to improve price realization. It aims to increase its export revenue share to approximately 40% of total sales, supported by 15 DMFs and 20 CEPs filed for regulated markets.

Profitability Margins

Profitability showed significant YoY improvement in Q2 FY26 with PAT margins rising to 5.2% from 3.6% (INR 30 Cr, up 56.7% YoY). However, margins saw a temporary sequential dip due to elevated fuel costs (Punjab floods). FY24 PAT margin stood at 6.31% (INR 135.42 Cr) but moderated to 4.8% (INR 101 Cr) in FY25.

EBITDA Margin

EBITDA for Q2 FY26 was INR 64 Cr, a 33.3% YoY increase, with margins expanding by 212 basis points to 11.1%. The company targets an EBITDA margin of 13-14% in the near term, expecting a 1-2% annual improvement through better product mix and operational leverage.

Capital Expenditure

IOLCP plans to fund its entire capex for the next three years through internal accruals. Recent investments are focused on automation, infrastructure upgrades, and scaling the differentiated API pipeline to support a 10-15% growth trajectory.

Credit Rating & Borrowing

The company maintains a strong credit profile with CARE A+ (Stable) for long-term and CARE A1+ for short-term facilities. Overall gearing is low at 0.24x as of March 31, 2025, with an interest coverage ratio of 14.27x.

⚙️ Operational Drivers

Raw Materials

Key raw materials include Acetic Acid (primary for Ethyl Acetate), Iso-Butyl Benzene (IBB), and various chemical intermediates for APIs like Metformin and Paracetamol. Raw materials are a major cost driver, with Ethyl Acetate and Ibuprofen accounting for 72% of FY24 revenue.

Import Sources

The company procures the majority of its raw materials for the chemical segment from China. API raw materials are primarily sourced from the domestic Indian market.

Capacity Expansion

Total blended manufacturing capacity reached 1,80,222 MTPA as of March 31, 2025, up from 1,72,962 MTPA in FY24. Paracetamol capacity utilization is currently 55-56%, with a target to reach 65% by next year.

Raw Material Costs

Raw material costs are volatile; for instance, Ethyl Acetate margins are highly sensitive to Acetic Acid price fluctuations. The company passes on cost increases to customers with a lag of approximately two months due to inventory processing cycles.

Manufacturing Efficiency

Efficiency is driven by integrated operations where chemical segment products serve as intermediates for the API segment, reducing overall cost structures and improving operating leverage.

📈 Strategic Growth

Expected Growth Rate

10-15%

Growth Strategy

Growth will be achieved by shifting the customer base from domestic to regulated markets (Europe/US) to capture higher margins, increasing Paracetamol capacity utilization to 65%, and expanding the API portfolio (Metformin, Clopidogrel, Pantoprazole). The company is also securing clearances for new land for future industrial expansion.

Products & Services

Major products include Ibuprofen (36% of sales), Ethyl Acetate (36% of sales), Metformin, Paracetamol, Clopidogrel, Fenofibrate, Pantoprazole, Acetyl Chloride, and Iso-Butyl Benzene.

Brand Portfolio

IOL Chemicals and Pharmaceuticals Limited (IOLCP).

New Products/Services

The company is scaling its 'differentiated API pipeline' and has recently introduced Metformin, Clopidogrel, and Fenofibrate to reduce product concentration risk.

Market Expansion

Targeting regulated markets with 18 approved CEPs and 15 DMFs. The company is specifically looking to grow its presence in the US and Europe to achieve a 40% export revenue share.

Market Share & Ranking

IOLCP is a well-established market leader in Ibuprofen globally, with an installed capacity of 12,000 MTPA.

🌍 External Factors

Industry Trends

The industry is shifting toward high-quality, regulated market manufacturing. IOLCP is positioning itself by moving away from the domestic-heavy mix to a 40% export-oriented model to capture stable demand and better pricing.

Competitive Landscape

The company faces competition from domestic and Chinese manufacturers in the API and Ethyl Acetate markets, leading to selling price pressure as seen in Q1 FY25.

Competitive Moat

The moat is built on backward integration and cost leadership in Ibuprofen. By manufacturing its own key starting materials (KSMs) like IBB, IOLCP maintains a favorable cost structure that is difficult for non-integrated competitors to match.

Macro Economic Sensitivity

The business is sensitive to global pharmaceutical demand and industrial chemical cycles. Inflation in fuel and raw material costs directly impacts the 11.1% EBITDA margin.

Consumer Behavior

Stable and growing global demand for essential APIs like Ibuprofen and Paracetamol supports long-term volume recovery.

Geopolitical Risks

Heavy reliance on China for raw materials (Acetic Acid) exposes the company to trade disruptions and geopolitical tensions between India and China.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to USFDA standards (Ibuprofen facility approved in FY20). Notably, IOLCP's products are not covered under the Drug Price Control Order (DPCO), allowing for more flexible pricing.

Environmental Compliance

The company is in the process of securing environmental clearances for new land. It has received approvals from pollution control boards and focuses on minimizing adverse impacts on health and safety.

Taxation Policy Impact

The effective tax rate resulted in a PAT of INR 30 Cr from a PBT level in Q2 FY26, reflecting standard corporate tax applications.

Legal Contingencies

As of March 31, 2025, no significant or material orders were passed by regulators, courts, or tribunals impacting the company's status as a going concern. No proceedings are admitted under the Insolvency and Bankruptcy Code.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the volatility of raw material prices from China, which can impact margins by 1-2% annually. Regulatory delays in new product approvals could also impact the 10-15% growth target.